PriceTargets.com logo

Strongbridge Biopharma - SBBP Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.00 As of 10/5/2021 01:00 AM ET
+0 (0.00%)
Get New Strongbridge Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SBBP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SBBP

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Strongbridge Biopharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.00.

This chart shows the closing price for SBBP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Strongbridge Biopharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/25/2021Craig HallumDowngradeBuy ➝ Hold$9.00 ➝ $3.25
5/25/2021JMP SecuritiesDowngradeOutperform ➝ Market Perform
3/4/2021HC WainwrightReiterated RatingBuy$10.00
1/7/2021HC WainwrightReiterated RatingBuy$10.00
10/30/2020HC WainwrightLower TargetBuy$18.00 ➝ $10.00
9/10/2020HC WainwrightReiterated RatingBuy$18.00
8/11/2020Jefferies Financial GroupReiterated RatingBuy$5.00
8/5/2020HC WainwrightReiterated RatingBuy$18.00
5/6/2020OppenheimerReiterated RatingBuy$6.00
3/3/2020Craig HallumInitiated CoverageBuy$7.50
2/26/2020OppenheimerBoost TargetOutperform$5.00 ➝ $6.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Strongbridge Biopharma logo
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.
Read More

Today's Range

Now: $2.00
Low: $1.95
High: $2.06

50 Day Range

MA: $2.09
Low: $1.89
High: $2.29

52 Week Range

Now: $2.00
Low: $1.85
High: $4.26

Volume

684,684 shs

Average Volume

866,464 shs

Market Capitalization

$135.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Strongbridge Biopharma?

The following Wall Street sell-side analysts have issued stock ratings on Strongbridge Biopharma in the last twelve months: StockNews.com.
View the latest analyst ratings for SBBP.

What is the current price target for Strongbridge Biopharma?

0 Wall Street analysts have set twelve-month price targets for Strongbridge Biopharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Strongbridge Biopharma in the next year.
View the latest price targets for SBBP.

What is the current consensus analyst rating for Strongbridge Biopharma?

Strongbridge Biopharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SBBP.

What other companies compete with Strongbridge Biopharma?

Other companies that are similar to Strongbridge Biopharma include Assembly Biosciences, Astria Therapeutics, Organogenesis, MBX Biosciences and Emergent BioSolutions. Learn More about companies similar to Strongbridge Biopharma.

How do I contact Strongbridge Biopharma's investor relations team?

Strongbridge Biopharma's physical mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company's listed phone number is (610) 254-9200 and its investor relations email address is [email protected]. The official website for Strongbridge Biopharma is www.strongbridgebio.com. Learn More about contacing Strongbridge Biopharma investor relations.